Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC promises equity boost in first official response to independent review
6 September 2022 - PHARMAC will supercharge its commitment to Māori and diverse communities, which could see different medicines funded, ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC releases its interim response following PHARMAC review
5 September 2022 - As part of its ongoing commitment to transparency, Te Pātaka Whaioranga – PHARMAC has today shared their ...
Posted by Michael Wonder on 05 Sep 2022
International work-sharing - first medicines approved by all five Access Consortium regulators
2 September 2022 - The TGA has approved two new medicines as part of the Access New Active-Substance Work-Sharing Initiative. ...
Posted by Michael Wonder on 05 Sep 2022
Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes
5 September 2022 - Approval marks the first SGLT-2 inhibitor approved in China for chronic kidney disease in adult patients ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 05 Sep 2022
Collaboration arrangement between the Department of Health and Aged Care and Health Technology Assessment bodies in the United Kingdom and Canada
5 September 2022 - The Department of Health and Aged Care has signed an international collaboration arrangement with five like minded ...
Posted by Michael Wonder on 04 Sep 2022
Australia among world's best in treating debilitating and often fatal muscle disorder
4 September - Australia has become one of the first countries in the world to fund a new, next-generation treatment ...
Posted by Michael Wonder on 03 Sep 2022
Pfizer/BioNTech bivalent COVID-19 booster approved by UK medicines regulator
3 September 2022 - The adapted COVID-19 vaccine targets both the original virus and the Omicron variant. ...
Posted by Michael Wonder on 03 Sep 2022
ATAGI update following weekly COVID-19 meeting (31 August 2022)
2 September 2022 - An update from the Australian Technical Advisory Group on Immunisation following their weekly meeting on 31 August ...
Posted by Michael Wonder on 03 Sep 2022
Every life is worth the same, but maybe not at PHARMAC
4 September 2022 - One of the dubious consequences of our obsession with race is the collection of data on ...
Posted by Michael Wonder on 03 Sep 2022
Swissmedic authorises Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as a booster in adults aged 18 and older
2 September 2022 - Novavax today announced that Swissmedic has expanded its temporary authorisation of Nuvaxovid COVID-19 vaccine in Switzerland for ...
Posted by Michael Wonder on 02 Sep 2022
The CEO of GoodRx doesn’t think mail order pharmacies are the ‘right answer’ to lowering prescription drug prices
2 September 2022 - Cartoonishly high hospital bills, overpriced prescription drugs, crowdsourcing for medical treatments—these are all features of the US ...
Posted by Michael Wonder on 02 Sep 2022
FDA still skeptical of ALS drug ahead of high stakes meeting
3 September 2022 - The U.S. FDA has posted another negative review of a closely watched drug for the deadly neurodegenerative ...
Posted by Michael Wonder on 02 Sep 2022
Call for Keytruda: Bay of Plenty couple needs help funding hefty cancer treatment
1 September 2022 - Tim Pardy thought he'd beat it. Five months later his pancreatic cancer not only returned, but it ...
Posted by Michael Wonder on 02 Sep 2022
Bayer’s Keredia (finerenone) receives updated label to include findings from Phase 3 FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes
1 September 2022 - US label now inclusive of data from comprehensive Phase 3 clinical trial program (FIGARO-DKD and FIDELIO-DKD) investigating ...